PRESCIENT THERAPEUTICS LIMITED (PTX)

Latest AI Signal: SELL
Status: EXPIRED
Days Old: 58

Confidence: 75.00%

Date: 24-03-2026

Price: $0.053

Last Price: $0.065

Post-Signal Low Price: $0.050

Latest  PRESCIENT THERAPEUTICS LIMITED(PTX)   News

15 Dec 2025, 01:29 PM

Just The Facts: Lindian Resources, Prescient Therapeutics, Tamboran Resources

In today's Just The Facts.. Lindian Resources has hosted senior US Government officials at its Kangankunde rare earths project in Malawi, highlighting development progress and its potential role in supplying high-grade rare earths to global markets, amid growing US focus on securing critical mineral

Sell Confidence High

AI Confidence - 75.00 % model confidence

Business Overview

Prescient Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing targeted cancer therapies, primarily leveraging its proprietary PTX-200 platform. The company operates in the oncology therapeutics market, aiming to address unmet needs in hematologic and solid tumor cancers, but remains pre-revenue with products in early to mid-stage clinical trials, limiting its current market position.

Financial Analysis

Cash Flow	Weak
Debt	Moderate
Profitability	Weak
Revenue Trend	Unknown

Technical Analysis

Trend	Bearish
Momentum	Weak
RSI Signal	Oversold
Support Level	$ 0.050
Resistance Level	$ 0.060

Valuation

Valuation - Unknown

Valuation is difficult to assess due to lack of revenue and earnings; heavily dependent on clinical trial outcomes and funding.

Catalysts

• Upcoming clinical trial data readouts.

• Potential partnerships or licensing agreements.

• Regulatory approvals or designations.

Recommendation

Action - Sell

Timeframe -

Given the weak technical indicators, high clinical risk, and limited financial strength, the stock is likely to face downward pressure in the near term. Investors should avoid exposure until clearer clinical progress or stronger financial footing emerges.